PRP for Plantar Fasciitis

Does PRP Work for Plantar Fasciitis?

Yes — platelet-rich plasma (PRP) has demonstrated clinically meaningful, durable pain relief for chronic plantar fasciitis across multiple randomized controlled trials. While cortisone injections act faster in the first few weeks, the preponderance of evidence shows PRP produces superior outcomes at six months, twelve months, and beyond, without the structural risks associated with repeated steroid use. Multiple systematic reviews and meta-analyses now support PRP as the preferred injection option for patients with plantar fasciitis that has failed conservative care. At Maryland Orthopedic Specialists, our board-certified orthopedic physicians offer ultrasound-guided PRP therapy for heel pain at our Bethesda and Germantown, MD locations, serving patients throughout Montgomery County and the greater Washington metropolitan area.

Understanding Plantar Fasciitis

Plantar fasciitis is the most common cause of heel pain, accounting for approximately 2 million patient visits annually in the United States. It represents roughly 11–15% of all adult foot complaints requiring medical attention.

The plantar fascia is a thick, fibrous band of connective tissue that originates at the medial calcaneal tuberosity (the underside of the heel bone) and fans forward to attach at the bases of the toes. Functionally, it supports the longitudinal arch of the foot through the "windlass mechanism" — the same tension system that propels you forward with each step. When this band is subjected to repetitive tensile overload, microscopic tears accumulate at the calcaneal insertion, triggering a cycle of failed healing and progressive tissue degeneration.

Despite its name, chronic plantar fasciitis is more accurately classified as plantar fasciopathy or fasciosis — a degenerative process rather than an inflammatory one. Histological studies consistently show collagen disorganization, angiofibroblastic hyperplasia, and the absence of significant inflammatory cell infiltrate in chronic cases. This pathological distinction is clinically important: it explains why anti-inflammatory treatments (including cortisone) provide only temporary symptom relief without resolving the underlying tissue pathology.

Common risk factors include:

• Tight Achilles tendon and calf complex (limited dorsiflexion)
• Elevated body mass index (BMI)
• Excessive foot pronation or high-arched cavus foot structure
• Occupations requiring prolonged standing on hard surfaces
• Rapid increase in running mileage or intensity
• Inappropriate footwear with inadequate arch support

The hallmark symptom is sharp, stabbing heel pain with the first steps in the morning or after periods of prolonged sitting — the so-called "post-static dyskinesia" pattern. Pain typically improves with a few minutes of walking, then may worsen again with prolonged activity. Without effective treatment, a substantial subset of patients develop chronic, activity-limiting heel pain that persists for twelve months or longer.

Why PRP for Plantar Fasciitis?

The biological rationale for PRP in plantar fasciitis stems directly from the degenerative pathology described above. Because chronic fasciopathy represents a failure of normal tissue repair rather than ongoing inflammation, the therapeutic goal is to stimulate healing, not suppress it.

PRP is prepared by centrifuging a small sample of the patient's own blood to concentrate platelets — cells whose alpha-granules contain a rich reservoir of growth factors including Platelet-Derived Growth Factor (PDGF), Transforming Growth Factor-beta (TGF-β), Vascular Endothelial Growth Factor (VEGF), and Epidermal Growth Factor (EGF). When injected directly into the area of degenerated fascia, these growth factors activate resident tenocytes, stimulate collagen synthesis, promote neovascularization, and initiate the tissue remodeling cascade that chronic fasciopathy cannot self-sustain.

Cortisone, by contrast, reduces pain through local anti-inflammatory effects and catabolic suppression of pain-signaling tissue. This explains why corticosteroid injections produce excellent short-term relief (2–6 weeks) but do not restore the structural integrity of the fascia. The degenerated tissue remains — and may actually be further weakened by repeated steroid exposure.

A key practical advantage of PRP for plantar fasciitis is precision delivery under musculoskeletal ultrasound. Our physicians use real-time ultrasound imaging to visualize the plantar fascia in cross-section, measure fascia thickness (normal: ≤4 mm; pathologic: typically 5–7 mm in symptomatic patients), identify the exact zone of maximal hypoechogenicity and degeneration, and guide the needle to the calcaneal enthesis with centimeter-level accuracy. This ensures the growth factors are deposited where the tissue pathology is greatest.

Clinical Evidence: Literature Review

Study 1 — Mahindra et al., Orthopedics, 2016

Citation: Mahindra P, Yamin M, Selhi HS, Singla S, Soni A. "Chronic Plantar Fasciitis: Effect of Platelet-Rich Plasma, Corticosteroid, and Placebo." Orthopedics. 2016;39(2):e285–e289. DOI: 10.3928/01477447-20160222-01

This double-blind RCT enrolled patients with chronic plantar fasciitis and randomized them into three groups: local PRP injection, corticosteroid injection, and placebo (normal saline). Patients were assessed on the Visual Analog Scale (VAS) for pain and the American Orthopaedic Foot and Ankle Society (AOFAS) Ankle-Hindfoot Score at baseline, 3 weeks, and 3 months.

Key findings: Both the PRP and corticosteroid groups showed statistically significant improvement over placebo at all timepoints. The corticosteroid group showed faster early improvement at 3 weeks. However, by 3-month follow-up, PRP was equivalent or superior to corticosteroid. Mean VAS scores decreased from 7.44 to 2.52 in the PRP group versus 7.72 to 3.64 in the corticosteroid group. Mean AOFAS scores improved from 51.56 to 88.24 in the PRP group versus 55.72 to 81.32 in the corticosteroid group at final follow-up — a clinically meaningful 6.9-point advantage for PRP on the AOFAS. The authors concluded PRP is "as effective as or more effective than corticosteroid" and noted PRP's trajectory continued to improve while cortisone effect leveled off.

Study 2 — Jain K et al., Foot & Ankle Surgery, 2015

Citation: Jain K, Murphy PN, Clough TM. "Platelet Rich Plasma versus Corticosteroid Injection for Plantar Fasciitis: A Comparative Study." Foot (Edinb). 2015;25(4):235–237. DOI: 10.1016/j.foot.2015.08.006

This comparative RCT enrolled 60 heels with intractable plantar fasciitis that had failed conservative management and randomized participants to PRP or corticosteroid injection. Outcomes were assessed using the Roles-Maudsley (RM) Score, VAS, and AOFAS score at 3, 6, and 12 months.

Key findings: At 3 months, all outcome scores improved significantly from baseline in both groups, with steroid scores marginally (but not statistically significantly) better. At 6 months, the trend shifted toward PRP equivalence. At 12 months, the PRP arm demonstrated statistically superior outcomes across all three measures: RM score 1.9 vs. 2.6 (P = .013), VAS 3.3 vs. 5.3 (P = .028), and AOFAS 88.5 vs. 75 (P = .033). The cortisone group's improvements had substantially deteriorated by the 12-month mark, while PRP outcomes were sustained. The authors' conclusion: "PRP is as effective as steroid injection at achieving symptom relief at 3 and 6 months after injection, for the treatment of plantar fasciitis, but unlike steroid, its effect does not wear off with time."

Study 3 — Sharma et al., BMC Musculoskeletal Disorders, 2023

Citation: Sharma R, Chaudhary N, Karki M, et al. "Effect of platelet-rich plasma versus steroid injection in plantar fasciitis: a randomized clinical trial." BMC Musculoskeletal Disorders. 2023;24:200. DOI: 10.1186/s12891-023-06277-1

This single-center, open-label, parallel-group RCT (NCT04985396) enrolled 90 participants aged 18–60 with chronic plantar fasciitis who had failed prior conservative care. Participants were randomized 1:1 to PRP injection (n = 45) or methylprednisolone injection (n = 45) and followed at 3 and 6 months. Primary outcomes were VAS pain scores, AOFAS scores, and plantar fascia thickness measured by high-resolution ultrasonography.

Key findings at 6 months: The PRP group demonstrated statistically superior outcomes on all three measures. Mean VAS was 1.97 ± 1.13 in the PRP group versus 2.71 ± 0.94 in the steroid group (group difference −0.73; 95% CI −1.18 to −0.28; P < .05). Mean AOFAS score was 86.04 ± 7.45 in the PRP group versus 81.23 ± 9.60 in the steroid group (group difference 4.80; 95% CI 1.15 to 8.45; P < .05). Plantar fascia thickness was significantly reduced to 3.53 ± 0.81 mm in the PRP group versus 4.58 ± 1.02 mm in the steroid group (P < .05), approaching the normal threshold of ≤4 mm only in the PRP group. Safety: No cases of plantar fascia rupture or heel fat pad atrophy were reported in either group.

Study 4 — Systematic Review and Meta-Analysis, Orthopaedic Journal of Sports Medicine, 2020

Citation: Hohmann E, Tetsworth K, Glatt V. "Platelet-Rich Plasma Versus Corticosteroids for Plantar Fasciitis: A Systematic Review of Randomized Controlled Trials." Orthop J Sports Med. 2020;8(8):2325967120915704. DOI: 10.1177/2325967120915704

This systematic review and meta-analysis identified 9 RCTs comparing 239 PRP patients to 240 corticosteroid patients and pooled VAS and AOFAS data at 1–1.5, 3, 6, and 12 months.

Key pooled findings: VAS scores favored PRP at every follow-up timepoint — at 1–1.5 months (MD −0.54; P = .004), at 3 months (MD −0.62; P < .00001), at 6 months (MD −0.88; P < .00001), and at 12 months (MD −1.63; P = .02). AOFAS scores were equivalent between groups at 1 and 3 months, but strongly favored PRP at 6 months (P < .00001) and 12 months (P < .00001). The authors assigned a Grade A recommendation to PRP for plantar fasciitis — the highest evidence grade — while noting no such grade could be assigned to corticosteroid at this level of evidence. No included study reported plantar fascia rupture in PRP-treated patients; steroid-associated rupture risk was documented in the literature at approximately 2.4%.

The Cortisone Risk Factor: What Patients Should Know

Corticosteroid injections are not without consequence when used repeatedly for plantar fasciitis. The documented structural risks include:

Plantar fascia rupture: Multiple studies have quantified the risk of fascial rupture following corticosteroid injections at approximately 1.4–2.4% per injection. A ruptured plantar fascia produces a distinctly different, often more disabling pain syndrome and may require months of protected weight-bearing. No comparable structural risk has been identified with PRP injections.

Heel fat pad atrophy: The heel fat pad — a specialized shock-absorbing structure — is susceptible to catabolic degradation from repeated cortisone exposure. Fat pad atrophy produces a painful, hard-to-treat syndrome that outlasts the original plantar fasciitis. It is not reversible.

Skin depigmentation and subcutaneous atrophy: Superficial steroid injection can permanently depigment overlying skin and reduce subcutaneous tissue volume, producing a cosmetically and structurally compromised heel.

For patients who have already received two or more cortisone injections, PRP becomes an especially important consideration — both because the structural risk of additional steroid exposure increases cumulatively, and because the window for PRP-stimulated biological repair remains open.

Patient Selection

• Plantar fasciitis present for ≥3 months, failed conservative care (stretching, orthotics, physical therapy) — Strongly appropriate
• Prior 1–2 cortisone injections with incomplete or waning relief — Strongly appropriate
• Patient wishing to avoid repeated cortisone exposure — Appropriate
• High-demand athlete requiring durable return to activity — Appropriate
• Acute plantar fasciitis (< 6 weeks), no prior treatment — Consider conservative care first; PRP if fails to respond
• Plantar fascia rupture on imaging — Surgical consultation may be indicated
• Active systemic infection, platelet disorder, or anticoagulation — Evaluate eligibility on individual basis

Treatment Protocol at Maryland Orthopedic Specialists

Pre-procedure: Patients discontinue NSAIDs (ibuprofen, naproxen, aspirin) for 2 weeks prior to injection, as NSAIDs inhibit platelet function and reduce PRP efficacy. Blood thinners are reviewed individually. Diagnostic ultrasound is performed at the initial visit to confirm plantar fascia thickness and identify the zone of maximum pathology.

Blood draw and preparation: Approximately 30–60 mL of peripheral blood is drawn from the patient's antecubital vein. The sample is centrifuged using a standardized double-spin protocol to separate and concentrate the platelet-rich plasma layer. The resulting PRP concentrate contains a platelet count 3–8 times higher than whole blood baseline.

Injection: Under continuous real-time ultrasound guidance, a small-gauge needle is positioned at the medial calcaneal enthesis — the precise anatomical zone of maximal fasciopathy. Approximately 3–5 mL of PRP is injected with a peppering or barbotage technique to distribute growth factors throughout the degenerated tissue.

Post-procedure protocol:

• Limit weight-bearing for 48–72 hours; use crutches if significant discomfort
• Expect a temporary "pain flare" lasting 3–7 days as the biological response initiates
• Begin gentle plantar fascia and calf stretching protocol at 1 week
• Use silicone heel cups or orthotic insoles for shock absorption
• Wear a night splint for the first 4–6 weeks to maintain plantar fascia at optimal length during healing
• Avoid NSAIDs for 2 weeks post-injection
• Physical therapy for progressive loading (eccentric heel raises, intrinsic foot strengthening) beginning at 2–3 weeks
• Avoid high-impact activities for 4–6 weeks

Return to activity timeline:

• Walking unrestricted: 1–2 weeks
• Low-impact exercise (swimming, cycling): 3–4 weeks
• Running and high-impact sport: 6–10 weeks depending on symptom response

Response trajectory: Most patients begin noticing meaningful improvement at 4–6 weeks, with continued improvement through 3–6 months. Clinical evidence shows PRP outcomes continue to strengthen through 12–24 months. A second PRP injection may be recommended at 6–8 weeks in patients with incomplete initial response.

Frequently Asked Questions